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Abstract 44 
The desire to reduce the number of animals used in experiments has highlighted the need to 45 
standardise and validate in vitro methods as alternatives to bioaccumulation studies using fish. 46 
The present work details a process based on five criteria to develop a list of reference 47 
compounds to evaluate alternative test methods to standard assays using rainbow trout 48 
(Oncorhynchus mykiss). The approach was based on: 1) inclusion of relevant chemical classes 49 
for bioaccumulation and supported by data on bioconcentration factor (BCF), whole body 50 
biotransformation rate (Kmet) and metabolic pathways (criteria 1-2); 2) cover a broad range of 51 
bioconcentration potencies, logarithmof octanol-water coefficient (Log Kow), metabolic 52 
susceptibility, molecular weight and maximum molecular diameter (criteria 3-4); and 3) 53 
identification of chemicals that are unsuitable for in vitro testing according to cut-off values for 54 
hydrolysis, volatility in solution and lipophilicity (criterion 5). In silico techniques were 55 
employed to predict maximal log BCF, Kmet and the metabolic pathway for those chemicals for 56 
which in vivo data for some of these properties were not available. Of the 139 compounds 57 
considered as reference compounds, 51 were supported by high quality in vivo BCF, 22 58 
compounds were supported by either in vivo Kmet or metabolic biotransformation data and ten 59 
chemicals did not pass volatility and lipophilicity cut-off values. The list of reference 60 
compounds is anticipated to provide a transparent basis for future experimental assessment of 61 
the applicability of alternative methods for bioaccumulation assessment within the larger 62 
scientific community.  63 
Keywords:  Bioaccumulation, reference list, Bioconcentration factor, Alternative testing, In 64 
vitro  65 
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Introduction 66 
The potential of a compound to bioaccumulate is one of many hazardous properties that needs 67 
to be evaluated in risk assessment procedures. Although bioaccumulation refers to the 68 
accumulation of a substance in an organism from all routes of exposure (from the environment 69 
and diet), the bioaccumulation of chemicals is usually expressed by the bioconcentration factor 70 
(BCF) that refers only to its accumulation from the environment in a waterborne exposure. In 71 
aquatic risk assessments, BCFs have been measured in fish according to the Organisation for 72 
Economic Cooperation and Development (OECD) Test Guideline305 [1-2].   73 
In vivo test systems for bioaccumulation are demanding in terms of resources and the use of 74 
large number of animals per test substance. Coupled with this, compliance with legislation such 75 
as the European Union REACH (Registration, Evaluation, Authorisation and restriction of 76 
Chemicals) regulation [3] has the potential to increase the demand for animal testing to assess 77 
bioaccumulation for a large number of chemicals. Other methods such as in silico (computer-78 
based) and in vitro techniques have been proposed as alternatives to in vivo testing since they 79 
comply better with the principles of the 3Rs (reduction, refinement and replacement) for animal 80 
testing [4]. 81 
In silico models for bioaccumulation have been developed for more than 30 years, mostly in 82 
the form of Quantitative Structure-Activity Relationships (QSARs) [5]. As chemical 83 
bioaccumulation is a steady-state phenomenon controlled predominantly by passive diffusion 84 
processes and lipid partitioning, the majority of these mathematical models have been based on 85 
relationships between the observed log BCF and hydrophobicity, often represented by the 86 
logarithm of n-octanol/water partition coefficient (log Kow). Whilst there is a strong 87 
relationship with hydrophobicity, the maximum bioconcentration of a chemical may be reduced 88 
by ionisation, poor chemical bioavailability in the water column and others factors that are 89 
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associated with the Absorption, Distribution, Metabolism and Excretion (ADME) properties of 90 
the chemicals [6-7].  91 
Of the ADME properties, absorption and metabolism have been implicated as factors 92 
introducing uncertainty into models for bioaccumulation [8]. To deal with factors that affect 93 
chemical absorption, in silico approaches have considered molecular properties to screen 94 
chemicals with limited bioaccumulation as a result of molecular constraints. In particular, 95 
molecular weight (MW) and maximum inter-atomic distance between two atoms in the 96 
chemical structure (Dmax) have been demonstrated to be useful descriptors [9-10]. Molecular 97 
descriptors have resulted in a variety of molecular cut-off values; however, there has been little 98 
consensus in the use. This can be explained partly by the fact that other features such as low 99 
bioavailability and extensive biotransformation of chemicals may also contribute to reduce 100 
bioaccumulation of large molecules [11]. To deal with uncertainties associated with 101 
metabolism, modelling studies have been incorporated chemical biotransformation data into the 102 
log Kow-based models to correct for the effect of metabolism in aquatic bioaccumulation [12]; 103 
however, the prediction of metabolic susceptibility employed have been based on mammalian 104 
predictions due to the lack of metabolic in vivo data for fish.  105 
A variety of fish cell-based methods have been developed to study the biotransformation of 106 
chemicals, mainly based on a depletion approach to calculate the hepatic clearance rate [8]. In 107 
vitro hepatic clearance data can be incorporated into physiologically-based models that allow 108 
for the extrapolation to whole animal biotransformation rates (Kmet) and the prediction of BCF 109 
[13-14]. In vitro test systems can also provide specific information on the metabolic pathway 110 
of a compound by identifying its resulting metabolites [15]. Although standardised protocols 111 
for subcellular fractions (S9) and primary hepatocytes spheroids in rainbow trout 112 
(Oncorhynchus mykiss) have recently been proposed [16-17], the applicability of in vitro assays 113 
for assessing chemical bioaccumulation is currently limited by methodological and technical 114 
7 
 
shortcomings as well as assay variability [18]. There is a need, therefore, to enable the 115 
development, standardisation and validation of in vitro methods for the prediction of in vivo 116 
bioaccumulation within a regulatory context [19].  117 
In order to ensure that non-animal methods can be used as surrogates for whole fish testing, the 118 
establishment of a high quality and well-parameterised relationship between in vivo and 119 
estimated data is required. A small number of such comparisons have been reported for 120 
bioaccumulation assessments [20-21], but they have been applied to a limited selection of 121 
chemicals. Therefore, a representative list of chemicals for bioaccumulation, chosen on the 122 
basis of defined criteria, is required in order to allow a scientifically transparent process for 123 
future data comparisons. 124 
The aim of this study was, therefore, to develop a list of reference compounds for rainbow trout 125 
for the evaluation of alternative methods as a potential surrogate, or compliment, to in vivo 126 
studies to assess chemical bioaccumulation. The development of a reference list was conducted 127 
according to a set of criteria that were applied to include a variety of chemical classes supported 128 
by data on BCF, Kmet and their potential biotransformation pathways. A broad coverage of log 129 
Kow, range of bioconcentration potential and molecular properties (MW and Dmax), and the 130 
identification of benchmark (control) chemicals and others with potential in vitro difficulties 131 
based on key physico-chemical properties (hydrolysis, volatility in solution and lipophilicity) 132 
were also pursued. This study shows the importance of in silico techniques to assist in the 133 
creation of the reference list of chemicals by the use of established in silico models and software 134 
for the prediction of chemical properties considered.  135 
Materials and methods 136 
Strategy for developing a reference list of compounds 137 
The development of a list of reference compounds was conducted according to the following 138 
criteria: 139 
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1. To include different chemical classes that were established to cover a broad range of 140 
metabolic reactions studied in fish and chemicals of environmental concern.   141 
2. To identify chemicals supported by in vivo/in silico data on BCF, Kmet and metabolic 142 
pathway for rainbow trout. 143 
3. To cover a broad range of lipophilicity and bioconcentration potential. 144 
4. To cover a broad range of molecular properties and metabolic susceptibility.  145 
5. To identify  chemicals with in vitro testing difficulties according to cut-off values for 146 
hydrolysis, volatility in solution and lipophilicity.  147 
These criteria were established using expert judgement based on previous criteria of the validity 148 
of the test procedures [22] and specific considerations for chemical bioaccumulation. 149 
Criterion 1 150 
Due to in vitro metabolism assays becoming more frequent in bioaccumulation studies, the first 151 
step in the strategy was the selection of the chemical classes that should be included in the 152 
reference list to cover all biotransformation routes characterised in fish [23]. Table 1 shows the 153 
18 chemical groups that were considered in this study with their main metabolic reaction and 154 
enzymes. Of these, Polycyclic Aromatic Hydrocarbons (PAHs) represent one of the most 155 
studied groups of chemicals using in vitro methods. For instance, benzo(a)pyrene is usually 156 
taken as a benchmark compound for the development of clearance assays such as S9 [16] and 157 
primary hepatocytes [20].  It should be noted that although little is known on fish metabolism 158 
for some chemical classes such as heterocyclic compounds, they represent a group of interest 159 
for research because of their wide agrochemical and pharmacological applications [24]. Other 160 
chemicals such as polychlorinated biphenyls (PCBs) and organophosphates (OP) were also 161 
included in this study since they have been considered chemicals of environmental concern. 162 
[Table 1 here] 163 
Criterion 2 164 
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The next step in the strategy was the selection of the appropriate fish species from which to 165 
obtain in vivo data, bearing in mind that in vivo data are available for many fishes including 166 
freshwater and marine species. Rainbow trout was chosen as being one of the eight OECD 167 
recommended test species for conducting flow-through in vivo bioconcentration studies [1-2] 168 
and for which different alternative approaches have been proposed [8]. 169 
Once the fish species was chosen, chemicals supported by in vivo data on BCF, Kmet and 170 
knowledge of the metabolic pathway for rainbow trout were compiled from different sources 171 
of information such as the scientific literature and BCF databases. In selecting chemicals based 172 
on available in vivo BCF data, those BCF values with the highest quality/reliability score 173 
assigned by the parent databases (refer to Table 2) and measured under the same experimental 174 
conditions were preferred. The experimental considerations were: 1) analytical determination 175 
of tissue concentrations of the test compounds in whole fish (wet weight) and; 2) experimental 176 
tests being conducted in a flow-through system and using the steady-state method for the 177 
calculation of the BCF. In addition, experimental data from organometallic compounds and 178 
organic salts were removed from the chemical selection due to the possibility that mechanisms 179 
other than hydrophobicity could strongly affect bioaccumulation of a compound [12]. Single 180 
BCF values for each chemical were obtained by averaging the multiple data points after the 181 
removal of statistically significant outliers and single BCF values for a test concentration. It 182 
should be noted that compounds with coefficient of variation (CV) of the reported BCF data 183 
higher than 0.5 and those presenting inconsistencies with their analogue chemicals were not 184 
considered further for the development of the reference list.  185 
When there were no in vivo BCF, Kmet and metabolic pathways data for a compound on the 186 
reference list, in silico techniques were used to predict these properties. These involved: 1) the 187 
bilinear model developed by Bintein et al [25] (stated as Equation 1) to build a maximal log 188 
BCF model (log BCFmax model) for rainbow trout; 2) the Arnot et al [26] QSAR model 189 
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developed from fish in vitro metabolism data to predict Kmet; and 3) Meteor, a commercial 190 
software for the prediction of the metabolic pathway of chemicals. 191 
Reference chemicals were thus classified into four types of compounds according to the 192 
presence of in vivo or in vitro data for BCF, Kmet and metabolic pathways as is shown in Figure 193 
1.  194 
[Figure 1 here] 195 
Criteria 3 and 4 196 
These criteria refer to achieving a broad range of lipophilicity (expressed by log Kow), 197 
bioconcentration potencies, molecular properties and metabolic susceptibility. Log Kow was 198 
selected amongst other physico-chemical descriptors due to its strong influence on BCF [5]. To 199 
establish a range of bioconcentration potencies, Gold-Standard BCF compounds were classified 200 
into three ranges depending on the difference between their reported in vivo BCF data and the 201 
predicted maximal BCF values. As a difference of 0.5 log BCF is assumed reasonable to 202 
account for the variability resulting from experimental procedures [27], compounds whose 203 
residuals were lower than 0.5 log units for this maximal log BCF were considered well-204 
predicted by log Kow. In this manner, compounds whose residuals were between 0.5 and 1 log 205 
units were considered moderately over-predicted, and compounds whose residuals were greater 206 
than 1 log unit were classified as highly over-predicted by the model. Among molecular 207 
descriptors, MW and Dmax were selected as they have been used widely to investigate the effect 208 
of molecular mass and size on chemical bioaccumulation [9-10]. Finally, predicted Kmet data 209 
were used as a measure of metabolic susceptibility.  210 
Criterion 5 211 
The last criterion was established to ensure chemical stability during the experimentation due 212 
to as this is considered one of the essential criteria for the validity of the test procedures [22]. 213 
Therefore, the identification of compounds that may be subject to abiotic degradation and/or 214 
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potentially significant adsorption to the test vessels was required to ensure their stability in in 215 
vitro test systems. The following chemical properties were considered relevant for the 216 
bioavailability and stability of compounds in the water phase: 1) volatility in solution 217 
(expressed by Henry’s Law constant (HLC)); 2) hydrolysis (expressed by half-life (HL) in 218 
water); and 3) lipophilicity (log Kow). The cut-off values for these properties were applied to 219 
identify compounds that were highly volatile in solution (log HLC <-11 atm(molL-1)-1), readily 220 
hydrolysed (HL <12 hours), and highly lipophilic (log Kow>8). The cut-off value for log HLC 221 
was taken from the physico-chemical constraints or indicators of low bioaccumulation proposed 222 
by Nendza et al [28]. The guidance on bioconcentration and bioaccumulation for the 223 
implementation of the REACH legislation [18] provided the cut-off value for HL on the basis 224 
of the assumption that the rate of hydrolysis of chemicals should be greater than 12 hours for it 225 
to be sufficiently absorbed by the organisms being exposed. The cut-off value of log Kow was 226 
taken from the analysis of the relationship between log Kow and in vivo log BCF of rainbow 227 
trout compounds conducted in this study, representing a potential threshold where reliable log 228 
BCF predictions could be obtained.   229 
Data extraction 230 
Reference chemicals were compiled from different sources of information. A thorough 231 
literature search was conducted to compile chemicals with in vivo data on Kmet and metabolic 232 
pathways for rainbow trout. However, a wider coverage of literature, involving other species 233 
and bioaccumulation endpoints, was needed with the aim to include all relevant chemicals 234 
established for the development of the reference list of chemicals (Table 1) and cover a broad 235 
range of chemical properties considered (criteria 3 and 4). 236 
Chemicals selected based on high quality in vivo BCF values for rainbow trout were obtained 237 
from the Environment Canada Domestic Substance List (DSL) and non-DSL Environment 238 
Canada databases, both reviewed by Arnot et al. [29] and the EURAS-CEFIC database [30]. 239 
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Table 2 lists the general features of the different databases in terms of their availability and 240 
format, BCF data contained therein and the score used to assess the quality of the data. It should 241 
be noted that although the databases differ in the number of criteria and scoring system, they 242 
all covered the crucial aspects reported in the guidance proposed by Parkerton et al [31] for 243 
evaluating in vivo fish BCF data. Such aspects include the correct analysis of test substance in 244 
both fish tissue and exposure medium, no significant adverse effects on exposed fish and 245 
achievement of steady-state with unambiguous units.  246 
[Table 2 here] 247 
In silico tools  248 
Calculation of physico-chemical descriptors 249 
Chemical structures of the compounds considered were obtained from the EPISuite v. 4.1 and 250 
were recorded as SMILES strings. SMILES strings were entered into different EPISuite models 251 
to calculate: 1) Log Kow from KOWWIN v.1. 68; 2) HLC from HenryWin v. 3.20; and 3) HL 252 
from the Fugacity model V. 253 
Calculation of molecular descriptors  254 
KOWWIN v.1. 68 was used to calculate the MW of chemicals. Dmax data were calculated from 255 
the geometry optimised 3-D structures (in xyz format). The 3-D structures were obtained using 256 
a Python v 2.7.3 script. The 3D geometries were generated using OpenBabel v. 2.3.2 257 
(http://:www.openbabel.org), accessed using Python via the Pybel module v. 1.8, and locally 258 
optimised using the MMFF94 force-field [32]. The MOPAC input files were extracted and 259 
MOPAC v. 2012 (http://openmopac.net/) was run to optimise the chemical structures using the 260 
AM1 Hamiltonian. The following keywords were employed: charge=0 and PRT INT (setting 261 
no charge and exporting the interatomic distances, respectively). Dmax values were obtained 262 
from the MOPAC.out file; Dmax being defined as the maximum interatomic distance between 263 
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non-hydrogen atoms. The Dmax values were extracted automatically from the MOPAC.out file 264 
using an in-house perl script.     265 
Identification of outliers 266 
Outliers for multiple BCF data were identified using the boxplot graph representation in the 267 
SPSS software v.18 (http://www.spss.co.in). In this simple analysis, outliers were identified as 268 
non-normally distributed when identified outside the T-bars (95% confidence intervals of the 269 
data). 270 
Development of a max log BCF model 271 
In order to calculate the potential of maximal bioconcentration (log BCFmax)for those chemicals 272 
that did not have in vivo BCF data for rainbow trout (see Figure 1), the development of a log 273 
BCFmax model was required. Equation (1), developed by Bintein et al [25], was re-built for a 274 
subset of chemicals that were supported by the highest in vivo BCF values using the Minitab v. 275 
16 statistical software (http://www.minitab.com). In addition, the log BCFmax model developed 276 
allowed for the identification of benchmarks or positive controls on the basis of their good 277 
correlation with log Kow (a difference of 0.5 log units between their predicted log BCF values 278 
log and observed log BCF). 279 
log BCF = 0.91 log Kow – 1.97 log (6.8 10-7 Kow + 1) - 0.79      (1) 280 
n = 154, r2 = 0.950, s = 0.347, F = 464 281 
Where: 282 
n is the number of observations 283 
r2 is the square of the correlation coefficient 284 
s is the standard error 285 
F is Fisher’s statistic 286 
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The model described by Bintein et al [25] was selected in preference to others due to the fact it 287 
was obtained using BCF values for freshwater fish (1/3 for rainbow trout), measured in whole 288 
fish (wet weight) and under flow-through conditions.  289 
Prediction of metabolic-related properties  290 
Kmet data estimated for a one kg fish were obtained from BCFBAF v.3.01 model of EPISuite 291 
and which is based on the QSAR model developed by Arnot et al [26]. 292 
The prediction of metabolic pathway and resulting metabolites was made using the Meteor 293 
software (Lhasa Limited, Leeds, England (www.lhasalimited.org/meteor/). Three levels were 294 
selected for the analysis: probable, plausible and equivocal. The structure of parent compounds 295 
were entered into .sdf format and the resulting metabolic pathway and metabolites were stored 296 
being available in the Supplementary Information.   297 
Results and discussion 298 
This study aimed to develop a list of reference compounds for the development, assessment and 299 
validation of the performance of alternatives methods to in vivo bioaccumulation studies for 300 
rainbow trout. As no official guidance is provided for conducting such a selection process, the 301 
current study presents a novel approach to identify, select and evaluate reference compounds.  302 
Similar to other chemical selection strategies in toxicity studies [33-35], the strategy followed 303 
in this study was based on a list of criteria established and the use of in silico techniques to 304 
assist in the selection process. It should be noted, however, that whilst for toxicity studies there 305 
is a need to consider the toxic mechanism and/or mode of action to ensure either consistency or 306 
diversity, bioaccumulation is governed by ADME processes that are more clearly linked to 307 
physico-chemical and molecular properties.  308 
According to the five criteria detailed above, a total of 139 chemicals were considered as being 309 
the best candidates for the development and assessment of non-animal methods for 310 
bioaccumulation (Table 3). Reference chemicals included the 18 chemicals classes listed in 311 
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Table 1 and a broad range of lipophilicity (log Kow: -2.25 to 12.11), bioconcentration potential 312 
(W, O1, O2), MW (30 to 959 g/mol), Dmax (0.18-2.65 nm) and metabolic susceptibility (Kmet: 313 
0 to 37.6). Details of the metabolic pathway and resulting metabolites for each compound are 314 
provided in Supplementary Information. Approximately half of the reference compounds were 315 
supported by in vivo data for some of these properties, and therefore they were considered Gold 316 
Standard compounds due to their role in the evaluation of the applicability of alternative 317 
methods. A set of 10 compounds were identified as a challenge for in vitro testing due to they 318 
did not pass the cut-off values for log HLC and log Kow. 319 
[Table 3 here] 320 
Gold Standard-BCF compounds 321 
Initially, investigation of the databases identified 354 in vivo BCF values for a total of 59 322 
chemicals that were obtained under the same experimental conditions and assessed with the 323 
highest reliability score. Table 4 lists the number of BCF values for individual chemicals, CV, 324 
the database from which they were retrieved and experimental features such as test 325 
concentration. As can be seen, the Environment Canada DSL and Non-DSL Databases 326 
contributed in approximately equal terms to the total number of experimental data, whereas a 327 
low percentage of compounds were in common between the EURAS-CEFIC database and 328 
either of the Environment Canada databases. Moreover, the majority of these compounds were 329 
found to be halogenated benzenes (40 %) and chloronitrobenzenes (20%) with a small number 330 
of compounds of environmental concern such OPs (53).  331 
[Table 4] 332 
BCFs values for 79 chemicals  failed to meet one or more of the established quality/reliability 333 
criteria of the databases [29-30] and thus they were not considered for the creation of a reference 334 
list of chemicals. Some examples of these unreliable compounds include the toxic effects 335 
reported for two dioxin-like compounds (e.g. tetradioxin), uncertain correction of the radiolabel 336 
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analysis for the parent compound for some organophosphates (e.g. tricresyl phosphate) and 337 
insufficient exposure duration to achieve 80% of steady-state for the majority of 338 
polychlorinated compounds (e.g. mirex). 339 
Only experimental data for rainbow trout were considered in order to avoid the variability in 340 
BCF that may be caused by data obtained from different species. Such variability of fish species 341 
may be a result of differences in biological factors and uptake kinetics [36]. However, 342 
differences in organism size and lipid content of the same fish species may explain the BCF 343 
variability obtained for the same compounds. Other factors such as strain, culturing conditions 344 
and different metabolic capacities due to different feeding regimens or/and seasonal variation 345 
could potentially explain some of the variability found in in vivo BCF data; however, they were 346 
not assessed due to the lack of such data in the original databases. 347 
Multiple BCF values were obtained for the majority of chemicals (Table 4). Compounds with 348 
CV > 0.5 were not included in the list of reference chemicals. Of these 59 chemicals, six 349 
compounds (20, 21, 23, 35, 31, 37) had CV higher values than the established and thus were 350 
rejected.  Additionally, 1,4-dichlobenzene (12) and 1,3,5-trichloro-2-ntirobenzene (16) were 351 
rejected as some discrepancies were found in comparison with their analogues. 352 
Single BCF values for each chemical were obtained by averaging the multiple data points after 353 
removal of statistically significant outliers. Furthermore, single data for a test concentration 354 
were also rejected for the average of the multiple BCF data points.  Figure 2 shows the box plot 355 
representation of the range of BCF values for the compounds considered. Three statistical 356 
outliers were identified (values for compounds 14, 24 and 33), which were excluded from use 357 
in the calculation of the average values for these compounds.  358 
[Figure 2 here] 359 
Development of a log BCFmax model for rainbow trout compounds and assignment of 360 
bioconcentration potencies  361 
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The 51 Gold Standard-BCF compounds obtained above were used to build a max log BCF 362 
model for rainbow trout compounds. Equation 1 (stated above) was modified to accommodate 363 
a subset of in vivo BCF data (represented as open circles in Figure 3). The bilinear log BCFmax 364 
model built is shown as a solid line in Figure 3 and was calculated using Equation 2. This model 365 
represents the worst-case scenario of bioconcentration driven by passive diffusion processes 366 
and which should be considered specific for rainbow trout. 367 
Log BCFmax = 0.88 log Kow – 1.73 log (2.25 10-6 Kow + 1) - 0.08   (2) 368 
It should be noted that the data used in Equation 2 (six compounds in total) were selected a 369 
priori to obtain the maximal BCF value and, therefore, there is no statistical significance to this 370 
relationship.  371 
[Figure 3 here] 372 
Compounds were classified into three bioconcentration potency ranges depending on the 373 
difference between their reported in vivo BCF data and predicted maximal BCF values (well-374 
predicted (residuals<0.5); moderately over-predicted (residuals=0.5-1) and highly over-375 
predicted (residuals>1)); Following this rationale, 29 compounds were classified as being well-376 
predicted compounds, 9 to be marginally over-predicted and another 13 substances were 377 
identified as being significantly over-predicted.  378 
The majority of well-predicted compounds were neutral compounds such as biphenyls (38-40, 379 
45, 48), halogenated benzenes (11, 13, 17, 19, 32-34, 41, 56) and alkylbenzenes (24, 25, 30). 380 
This observation is supported by the lack of polar groups in the chemical structure that may 381 
make them less susceptible to a metabolic attack [5]. Following the same rationale, most 382 
compounds that were moderately over-predicted by Equation 2 were polar compounds such as 383 
nitrochlorobenzenes (for example compounds 6-8). However, hydrophobic compounds (log 384 
Kow <3) with polar groups in their structure (2-5) were also well predicted by Equation 2. This 385 
finding indicates that the high biotransformation potential of hydrophilic compounds is unlikely 386 
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to affect their bioaccumulation significantly. This is in agreement with previous in silico 387 
predictions that observed that high rates of chemical flux across the gills could be more 388 
significant than the biotransformation rates for bioaccumulation of hydrophilic compounds [15, 389 
37]. 390 
Highly over-predicted compounds included other nitrobenzenes (14, 15, 28), triphenyl 391 
phosphite (53), pentabromomethylbenzene (54) and ionic compounds such as phenolics (18, 392 
36) and hydrophobic organic acids (49-52, 55, 58). The low observed log BCF of the OP 393 
compound may be a result of metabolism, since modelling studies that have shown that 394 
relatively low biotransformation rates may have a large influence on bioaccumulation for 395 
hydrophobic compounds [15,37]. As expected, the observed log BCF of ionisable compounds 396 
in this study was low, as the bioaccumulation of ionisable compounds is not primarily driven 397 
by hydrophobicity [6]. Rather, a mechanistic model for the uptake and elimination of ionisable 398 
compounds via fish gills [38] showed that although ionisable compounds are less bioavailable 399 
than neutral species, in terms of crossing biological membranes, they can maintain a high 400 
diffusion across epithelial cell membrane which is comparable to neutral molecules. 401 
Consequently, descriptors other than log Kow have been considered in recent in silico studies 402 
to improve the predictions of bioaccumulation for ionisable compounds. Alternative descriptors 403 
include the logarithm of the distribution coefficient (log D), which is the ratio of concentration 404 
of unionised forms of a compound in octanol and the total concentration of unionised and 405 
ionised forms in water [39-40].  406 
It is worth noting that due to the fact that the bioaccumulation of a compound is a complex 407 
function comprising diverse physiological and biological processes, the reduced 408 
bioconcentration of some of these highly over predicted substances could be associated with 409 
more than one factor [11]. For example, the relatively high molecular size (Dmax= 1.16 to 1.20), 410 
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such as that of carboxylic acid compounds (49-52, 55), may also have contributed to reduction 411 
in BCFs. 412 
Gold Standard- metabolic  compounds  413 
Of the 139 reference compounds listed in Table 3, 22 were classified as Gold Standard 414 
metabolic compounds including Gold Standard -Kmet and MP compounds. Table 5 lists the in 415 
vivo data and other experimental details, amongst others, type of exposure, uptake phase and 416 
test concentration. In particular, eight pesticides (triazoles) (1-8) [41], two insecticides (9-10) 417 
[42] and four PCBs (11-14) [43] were found with in vivo Kmet data determined through a dietary 418 
exposure using juvenile rainbow trout. The Kmet data were calculated by comparing their HL 419 
with known recalcitrant PCBs in non-linear relationship between log Kow and HL developed 420 
by Fisk et al [44]. Based on this approach, chemicals whose HL fall on, or near, this non-linear 421 
relationship are assumed to not undergo high metabolism processes (recalcitrant), whereas 422 
those chemicals that fall below this relationship are suggested to be biotransformed. This 423 
method allows for the quantification of the biotransformation rates of organic chemicals that 424 
are tested using the same experimental conditions. 425 
A total of eight chemicals were compiled from the literature whose resulting metabolites were 426 
analysed in an in vivo system, and which are referred to Gold Standard-MP compounds in Table 427 
3. As Table 5 shows, these chemicals included four perfluoroalkylated compounds (15-18) [45-428 
46], decabromodiphenyl ether (19) [47] and three carboxylic acid pharmaceuticals (20-22) [48-429 
49]. Although few metabolites were monitored for each compound, the whole 430 
biotransformation pathway was proposed for compounds 18,20,21,22. Depending on the study, 431 
different routes of exposure (dietary, waterbone, intraperitoneal injection) as well as fish tissues 432 
for analysis (muscle, blood, liver bile, kidney) were used to investigate the biotransformation 433 
pathways of Gold Standard-MP compounds. Worthy of mention is that both aspects may 434 
influence the formation and accumulation of resulting metabolites from the parent compound. 435 
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For instance, a different metabolic pattern was found for decabromodiphenyl ether (19), where 436 
debrominated diphenyl ethers metabolites (De-BDEs) were the main metabolites in liver, 437 
whereas methoxylated diphenyl ethers (MeO-BDEs) were found in higher concentration in 438 
blood [47]. It should be noted that different metabolites of ibuprofen (IBF) were found by 439 
comparing two types of exposure: a waterborne exposure with four additional pharmaceuticals 440 
[48] and on its own [49]. Whilst the hydroxylated and acyl glucuronide metabolites of IBF were 441 
reported in both studies, taurine conjugates of IBF were only reported in organisms that were 442 
exposed to a single waterborne exposure of IBF [49]. 443 
[Table 5 here] 444 
Supplementary compounds  445 
Although this study prioritised the selection of chemicals for in vivo data for rainbow trout, not 446 
all chemical classes listed in Table 1 were covered. As it was observed above, in vivo BCF 447 
compounds were mostly halogenated aromatic chemicals. This lack of diversity for some types 448 
of chemicals such as reactive compounds, could be explained by the fact such chemicals are 449 
likely to cause higher mortalities and adverse effects than the 10% of the limit established for 450 
the validity of OECD protocols [1-2] and hence will not be good candidates for in vivo 451 
bioaccumulation assessments. This observation is supported by the toxic effect reported for 452 
dioxin-type compounds described above. Nonetheless, the identification of the lack of in vivo 453 
data for certain chemical classes could provide a basis for the selection of chemicals for future 454 
in vivo BCF testing in rainbow trout [2].  455 
To facilitate the correct development and validation of alternative methods for bioaccumulation, 456 
67 compounds were added to the list to cover all relevant chemical classes presented in Table 457 
1. Generally, the complementary chemicals were extracted from the review of 458 
biotransformation in fishes [23], metabolism studies on different species such as mammals and 459 
others using rainbow trout aimed to provide additional information for future in vitro assays. 460 
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Supplementary chemicals encompassed a set of halogenated compounds (6-9) [50],six PAHs 461 
(42-47) [51], five heterocyclic compounds (58-62) [23,24,52] the majority of OPs (66-69) [53], 462 
and the complete set of organosulfur compounds (71-77) [23,54-56], amines and amides (99-463 
114) [23,52,57], aldehydes (115-118) [58-59], alcohols (119-122) [23,60-61],  quinones (127-464 
131) [23,62-64], epoxides (132-136) [65] and polyunsaturated fatty acids (137-139) [23]. 465 
Compounds with testing difficulties 466 
All 139 compounds compiled in Table 3 were screened according to the cut-off values defined 467 
in the last criterion of our strategy. Of these, six compounds (57,61,62,84,106,114) had log 468 
HLC lower values than the established cut-off, and four chemicals (29,41, 137,139) did not 469 
pass the criteria for lipophilicity. Since these compounds may be highly volatilite in solution 470 
and there may be potentially significant  adsorption to the test vessels respectively, special 471 
considerations should be taken into account to ensure their chemical stability in the in vitro 472 
assays. It should be noted that although all compounds passed the criteria for hydrolysis, 473 
chemicals with HL of 208 hours (100,101,119), and even those with values of 360 (as indicated 474 
in Table 3) could require further attention in long-term assays to avoid the loss of the parent 475 
compound.  476 
Other reported properties that may limit the bioaccumulation of chemicals, such as ready 477 
biodegradability and phototransformation were not taken into account in this study. This is due 478 
to the fact that readily biodegradable molecules can bioaccumulate if their uptake rate is greater 479 
than the rate of degradation [19], and for phototransformation processes are expected to be less 480 
significant under laboratory lighting conditions than under field conditions [31]. 481 
List of reference compounds: Further considerations and implications 482 
The present list of 139 chemicals (Table 3) could  undergo a refinement of the chemical 483 
selection process under project-specific requirements. For instance, other essential criteria for 484 
the selection of test chemicals [22] such as known and high consistent purity and commercial 485 
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availability should be applied to the present list of chemicals to select a set of compounds for 486 
in vitro testing.  Moreover, the possibility of a compound to be quantifiable by an analytical 487 
method and its existing in vitro data for rainbow trout (as indicated in Table 3) could be also 488 
taken into account in the making-decision process.  489 
When selecting chemicals within the same chemical group, chemicals with broader values for 490 
log Kow, molecular properties and Kmet should be selected with the aim to ensure a wider 491 
domain for these properties according to criteria 3 and 4 of this study. Furthermore, additional 492 
compounds can be added to the list expanding the chemical domain as appropriate.    493 
Previous work has assigned positive controls in reference lists proposed for the development of 494 
alternatives methods to in vivo testing [33, 35]. Of the 139 reference chemicals presented in this 495 
study, chemicals with a neutral (non-ionised) structure that were well-predicted by Equation 2 496 
(identified in Table 3) could be considered as positive controls or benchmark compounds since 497 
their bioaccumulation is expected to be driven mainly by passive diffusion processes. However, 498 
and no less important, is the consideration of the over-predicted chemicals (O1 and O2 499 
compounds in Table 3)due to the fact they might be susceptible to moderate metabolism (e.g. 500 
nitrocholobenzenes) and/or poor bioavailability (e.g. ionisable compounds); and thus in vitro 501 
test systems for metabolism may assist in elucidating where significant biotransformation 502 
processes impact on BCF, helping to clarify uncertain in vivo OECD measurements. Similarly, 503 
future development and improvement of aquatic non-animal tests for absorption could provide 504 
more information on the uptake processes of low bioavailable chemicals  and a better 505 
understanding of molecular constraints on chemical absorption at a cellular level. 506 
We believe that a successful development and validation of fish in vitro assays is the key for 507 
the correct use of non-animal methods in bioaccumulation tests. This is due to fact the various 508 
benefits can be obtained from the validation of such assays.. For instance, accurate in vitro data 509 
could enhance the knowledge of in vivo absorption and metabolism processes, allowing a better 510 
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understanding of how both processes can influence in vivo assessment of chemical 511 
bioaccumulation in fish. In addition, in vitro metabolic data could be incorporated into the log 512 
BCFmax model developed for rainbow trout compounds to correct for the effect of metabolism 513 
on bioaccumulation and refine the estimates of kmet and metabolic pathways.  And from 514 
regulatory perspective, in vitro assays potentially could be used together with in silico methods 515 
in a tiered approach to prioritise chemicals for future in vivo testing in order to reduce animal 516 
use.  517 
Conclusions  518 
There is an urgent need to develop and validate non-animal methods to assess bioaccumulation 519 
of chemicals in fish. A successful development of alternative test systems to in vivo testing 520 
could provide not only accurate information on ADME processes for a given compound, but 521 
also they could be used in risk assessment procedures to reduce the number of fish for 522 
experimentation.  523 
The present work has introduced a fully transparent description of an approach applied to 524 
develop a list of reference chemicals for the development of non-animal methods to assess 525 
chemical bioaccumulation. The rationale employed in this study was based on five established 526 
criteria. An in silico approach was required to develop a log BCFmax model for rainbow trout, 527 
explore the bioconcentration potential of examined chemicals and assist in the development of 528 
the list of reference compounds. As a consequence of this work, a reference list of 139 529 
chemicals including 18 different chemical classes is proposed to facilitate the evaluation of 530 
alternative methods to in vivo testing for rainbow trout. It is envisioned that using this list of 531 
reference compounds may enhance our understanding of the relationship between in vivo and 532 
in vitro data by providing a common basis for experimental effort, and through such effort 533 
facilitate the refinement of in silico prediction of BCF, Kmet and metabolic pathways of 534 
chemicals for one of the most common fish species used in regulatory testing. 535 
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Figure legends 755 
 756 
[Figure 1] Classification of reference compounds into four groups based on the presence of in 757 
vivo or in vitro data on BCF, Kmet and metabolic pathways. 758 
[Figure 2] Boxplot representation of the range of BCF values for the 59 chemicals listed in 759 
Table 4.  Outliers represented as open circles. 760 
[Figure 3] Relationship between and log BCF (L/Kg) ww log Kow for the Gold Standard-BCF 761 
compounds. Solid line: log BCFmax model (Equation 2) developed from a set of chemicals with 762 
high values (represented as open circles). Long-dashed line: Log BCFmax model-0.5. Short-763 
dashed line: Log BCFmax model -1. W: well-predicted compounds (residuals < 0.5 log units), 764 
O1: marginally over-predicted compounds (residuals > 0.5), O2: Highly over-predicted 765 
compounds (residuals > 1) according to log BCFmax predictions. 766 
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Table 1. Chemicals classes considered for the development of a reference list of chemicals and their main known biotransformation reactions in 
fish. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 792 
  793 
No. Chemical class Studied biotransformation reaction (enzyme) [23] 
1 Aliphatic halogenated hydrocarbons Phase I:  Oxidative dehalogenation(CYPs) 
Phase II: GSH conjugation (GSTs) 2 Aromatic halogenated hydrocarbons 
3 Heterocyclic compounds 
Phase I:  Oxidation, reduction (CYPs) 
Phase II: Glucuronidation (UGTs) 
4 Polycyclic aromatic hydrocarbons  
Phase I:  Hydroxylation, ( CYPs) 
Phase II: GSH conjugation ( GSTs) 
5 Polychlorinated biphenyls  
Phase I:  Hydroxylation ( CYPs ) 
Phase II: Glucuronidation ( UGTs) 
6 Organosphosphorus  
Phase I: Oxidative desulfuration (CYPs) 
               Hydrolysis (CES) 
7 Organosulfur compounds  Phase I: Oxidation (FMOs) 
8 Carboxylic acids Phase II: Amino acid conjugation (AAT) 
9 Nitroaromatic compounds Phase I:  Reduction (NTR) 
10 Aliphatic amines Phase I:  Oxidation ( CYPs, MAO,FMOs) 
               Reduction ( CYPs) 
Phase II: Glucuronidation ( UGTs) 
                Sulfonation (SULT) 
                Acetylation ( Acetyl-CoA) 
11 Aromatic amines 
12 Amides Phase II: Glucuronidation ( UGTs) 
13 Aldehydes Phase I:  Oxidation (AO, ALDH) 
14 Alcohols  
Phase I:  Oxidation (ADH) 
Phase II: Sulfonation (SULT) 
15 Phenols  
Phase II: Glucuronidation ( UGTs) 
               Sulfonation (SULT) 
16 Quinones Phase I:  Reduction (DTD) 
17 Epoxides Phase I:  Hydrolysis (EH) 
18 Polyunsaturated fatty acids Phase I:  Oxidation (LPO) 
39 
 
AAT: Aminoacyl transferase, Acetyl-CoA: Acetyl-coenzyme A, ADH: Alcohol dehydrogenase, ALDH: Aldehyde dehydrogenase, AO: Aldehyde 
oxidase, CES:Carboxylesterase, CYPs: Cytochrome P450, DTD: DT Diaphorase, EH: Epoxide hydrolase, FMOs: Flavin-containing 
monooxygenase, GSTs:Glutathione S-transferase, LPO: Lipoxygenase, MAO: monoamine oxidase, NTR: Nitroreductasa, SULT: 
Sulfotransferasa, UGTs: UDP-glucuronosyl transferase. 
 794 
 795 
 796 
 797 
 798 
 799 
 800 
 801 
 802 
 803 
 804 
 805 
 806 
 807 
40 
 
Table 2. A summary and comparison of the data and features of the BCF databases. 808 
 Environment Canada BCF  databases EURAS-CEFIC database 
Source On request from 
http://www.hc-sc.gc.ca 
Freely available from 
http://ambit.sourceforge.net/euras/ 
Format Microsoft excel spreadsheet Microsoft excel spreadsheet 
No.  BCF values 5317 1130 
No. chemicals 822 549 
Species Fish (82%), invertebrates (15%) 
autotroph (4%) 
Only fish (90% for Common carp) 
Score system 1 (high), 2 (moderate), 3 (low) Klimisch score: 1 (reliable without restrictions), 2 (reliable 
with restrictions), 3 (not reliable), 4 (not assignable) 
 
 809 
 810 
 811 
 812 
 813 
 814 
 815 
 816 
 817 
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Table 3. List of reference compounds for the development and evaluation of alternative methods to in vivo fish bioaccumulation 818 
studies. 819 
ID 
Cc 
(T1) 
Chemical name CAS RN 
Type 
(F1) 
Log 
Kow 
MW 
(g/mol) 
Dmax 
(nm) 
Log 
BCF 
 Kmet 
(1/d) 
MP and 
Ms (pp) 
Notes Ref 
Ref 
ed 
1 1 γ-Lindane 58-89-9 GS-BCF  4.26 290.83 0.68 3.13 0.01 1-2 W, control 1 Nd 
2 1,12 Perfluorooctanesulfonamide 754-91-6 GS-MP 5.80 499.14 1.40 4.34 0.01 3,T5  [45] Nd 
3 1,14 10:2 Fluorotelomer alcohol 865-86-1 GS-MP 7.08 564.13 1.60 3.63 0.00 4-5,T5  [45] Nd 
4 1,14 8:2 Fluorotelomer alcohol 678-39-7 GS-MP 5.75 464.12 1.34 4.35 0.01 6-7,T5  [45] [13] 
5 1 8:2 Fluorotelomer acrylate 27905-45-9 GS-MP 7.11 518.17 1.70 3.60 0.01 8-9,T5  [47] [66] 
6 1 Tetrachloromethane 56-23-5  SP 2.44 153.82 0.50 2.06 0.17 10  [50] Nd 
7 1 Trichloroethane 79-00-5  SP 2.01 133.40 0.37 1.68 0.50 11-12  [50] Nd 
8 1 Vinyl chloride 75-01-4  SP 1.62 62.50 0.37 1.34 0.72 13-14 HL=360 h [50] Nd 
9 1 Dichloromethane 75-09-2  SP 1.34 84.93 0.24 1.09 0.88 15  [50] Nd 
10 2 1,2-Dichlorobenzene 95-50-1 GS-BCF  3.28 147.00 0.56 2.58 0.06 16-17 W, control 1 Nd 
11 2 1,3-Dichlorobenzene 541-73-1 GS-BCF  3.28 147.00 0.56 2.74 0.06 18-19 W, control 1 Nd 
12 2 1,2,3-Trichlorobenzene 87-61-6 GS-BCF  3.93 181.45 0.59 3.26 0.04 20-21 W, control 1 Nd 
13 2 1,2,3,4-Tetrachlorobenzene 634-66-2 GS-BCF  4.57 215.89 0.59 3.85 0.02 22-23 W, control 1 Nd 
14 2 Pentachlorobenzene 608-93-5 GS-BCF  5.22 250.34 0.64 4.19 0.02 24 W, control 1 Nd 
15 2 1,3-Dibromobenzene 108-36-1 GS-BCF  3.77 235.90 0.60 2.82 0.08 25-26 W, control 3 Nd 
16 2 1,3,5-Tribromobenzene 626-39-1 GS-BCF  4.66 314.80 0.60 4.02 0.05 27 W, control 3 Nd 
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Table 3. List of reference compounds for the development and evaluation of alternative methods to in vivo fish bioaccumulation 820 
studies (cont.) 821 
 822 
 823 
ID 
Cc 
(T1) 
Chemical name CAS RN 
Type 
 (F1) 
Log 
Kow 
MW 
(g/mol) 
Dmax 
(nm) 
Log 
BCF 
 Kmet 
(1/d) 
MP and 
Ms (pp) 
Notes Ref 
Ref 
ed 
17 2 1,2,4-Tribromobenzene 615-54-3 GS-BCF  4.66 314.80 0.60 3.63 0.05 28 W, control 3 Nd 
18 2 1,2,4,5-Tetrabromobenzene 636-28-2 GS-BCF  5.55 393.70 0.67 3.67 0.04 29 O1 3 Nd 
19 2 Hexabromobenzene 87-82-1 GS-BCF  7.33 551.49 0.67 3.02 0.03 30 W, control 2 Nd 
20 2 1,2,4-Trichloro-5-
methylbenzene 
6639-30-1 GS-BCF  4.47 195.47 0.59 3.88 0.04 31-32 W, control 3 Nd 
21 2 1,2,4,5-Tetrachloro-3,6-
dimethylbenzene 
877-10-1 GS-BCF  5.67 243.95 0.70 3.55 0.03 33 O2 2 Nd 
22 2 Pentachlorotoluene 877-11-2 GS-BCF  5.76 264.36 0.75 3.83 0.02 34 O2 2 Nd 
23 2 Pentabromomethylbenzene 87-83-2 GS-BCF  6.99 486.62 0.70 2.43 0.02 35 O2 2 Nd 
24 2 Pentabromoethylbenzene 85-22-3 GS-BCF  7.48 500.65 0.72 2.52 0.02 36 O1 2 Nd 
25 2 2,4-Dichloro-1-
(trifluoromethyl)benzene 
320-60-5 GS-BCF  4.24 215.00 0.69 3.52 0.02 37 W, control 2 Nd 
26 2 1,2-Dichloro-4-
(trifluoromethyl)benzene 
328-84-7 GS-BCF  4.24 215.00 0.69 3.18 0.02 38-39 W, control 3 Nd 
27 2 1,2,3-Trichloro-4-
methoxybenzene 
54135-80-7 GS-BCF  4.01 211.47 0.75 3.25 0.01 40-42 W, control 3 Nd 
28 2 Pentachloroanisole 1825-21-4 GS-BCF  5.30 280.36 0.80 4.19 0.00 43 W, control 2 Nd 
29 2 Decabromodiphenyl ether 1163-19-5 GS-MP 12.1
1 
959.17 1.08 -0.62 0.00 44,T5 Highly 
lipophilic 
[47] [67] 
30 3 2,3-Dichloro-1,1'-biphenyl 16605-91-7 GS-BCF  5.05 223.10 0.93 4.08 0.01 45-46 W, control 2 Nd 
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Table 3. List of reference compounds for the development and evaluation of alternative methods to in vivo fish bioaccumulation 824 
studies (cont.) 825 
 826 
ID 
Cc 
(T1) 
Chemical name CAS RN 
Type 
 (F1) 
Log 
Kow 
MW 
(g/mol) 
Dmax 
(nm) 
Log 
BCF 
 Kmet 
(1/d) 
MP and 
Ms (pp) 
Notes Ref 
Ref 
ed 
31 3 2,5-Dichloro-1,1'-biphenyl 34883-39-1 GS-BCF  5.05 223.10 0.93 3.98 0.01 47-49 W, control 2 Nd 
32 3 3,5-Dichloro-1,1'-biphenyl 34883-41-5 GS-BCF  5.05 223.10 0.92 3.77 0.01 50 W, control 2 Nd 
33 3 2,2',5-Trichloro-1,1'-biphenyl 37680-65-2 GS-BCF  5.69 257.54 0.93 4.23 0.00 51-52 W, control 2 Nd 
34 3 2,2',5-Trichloro-1,1'-biphenyl 20020-02-4 GS-BCF  5.75 265.95 0.70 5.23 0.01 53 W, control 2 Nd 
35 3 2,2',3,3'-Tetrachloro-1,1'-
biphenyl 
38444-93-8 GS-BCF 
and Kmet  
6.34 291.99 0.93 4.23 0.00 54-55 W, control 2, 
[43] 
Nd 
36 3 p,p'-
Dichlorodiphenyltrichloroetha
ne 
50-29-3 GS-Kmet  6.79 354.49 1.04 3.85 0.01 56-57  [43] Nd 
37 3 2,2',3,3',4,6'-Hexachloro-
1,1'-biphenyl  
38380-05-1 GS-Kmet  7.62 360.88 0.89 3.19 0.00 58-60  [43] Nd 
38 3 2,2',3,3',5,6'-Hexachloro-
1,1'-biphenyl  
52744-13-5 GS-Kmet  7.62 360.88 0.93 3.19 0.01 61-62  [43] Nd 
39 3 2,2',3,3',6,6'-
Hexachlorobiphenyl-1,1'-
biphenyl 
38411-22-2 GS-Kmet  7.62 360.88 0.93 3.19 0.00 63-65  [43] Nd 
40 4 1,4-Dichloronaphthalene 1825-31-6 GS-BCF  4.46 197.06 0.77 3.75 0.02 66-67 W, control 3 Nd 
41 4 Octachloronaphthalene 2234-13-1 GS-BCF  8.33 403.73 0.78 2.58 0.00 68 W, control. 
Highly 
lipophilic 
2 Nd 
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Table 3. List of reference compounds for the development and evaluation of alternative methods to in vivo fish bioaccumulation 827 
studies (cont.) 828 
ID 
Cc 
(T1) 
Chemical name CAS RN 
Type 
 (F1) 
Log 
Kow 
MW 
(g/mol) 
Dmax 
(nm) 
Log 
BCF 
 Kmet 
(1/d) 
MP and 
Ms (pp) 
Notes Ref 
Ref 
ed 
42 4 9H-Fluorene 86-73-7 SP 4.02 166.22 0.84 3.43 0.15 69-70 HL=360 h [51] Nd 
43 4 Phenanthrene 85-01-8  SP 4.35 178.23 0.87 3.70 0.08 71-72  [51] [68] 
44 4 Anthracene 120-12-7  SP 4.35 178.23 0.90 3.70 0.08 73-74  [51] Nd 
45 4 Fluoranthene 206-44-0  SP 4.93 202.25 0.91 4.11 0.08 75  [51] Nd 
46 4 Benzo(a)pyrene 50-32-8 SP 6.11 252.31 1.04 4.26 0.23 76-77  [51] [16,2
0,58] 
47 4 Benzo(a)anthracene 56-55-3 SP 5.52 228.29 1.15 4.34 0.07 78-79  [51] Nd 
48 5 Dehydroacetic acid 520-45-6 GS-BCF  0.78 168.15 0.82 2.12 36.91 80 U, HL=360 h 1 Nd 
49 5 Myclobutanil 88671-89-0  GS-Kmet  3.50 288.78 1.10 2.98 0.20 81-82  [41] [69] 
50 5 Propiconazole 60207-90-1  GS-Kmet  4.13 342.22 1.18 3.52 0.57 83-84  [41] [69] 
51 5 Cyproconazole 94361-06-5 GS-Kmet  3.25 291.78 1.07 2.77 0.37 85-86  [41] Nd 
52 5 Penconazole 66246-88-6 GS-Kmet  4.67 284.18 1.01 3.94 0.21 87-88  [41] Nd 
53 5 Metconazole 125116-23-
6 
GS-Kmet  4.19 319.83 1.05 3.57 0.58 89-90  [41] [69] 
54 5 Triadimefon 43121-43-3 GS-Kmet  2.94 293.75 1.14 2.50 0.54 91-93  [41] [69] 
55 5 Tetraconazole 112281-77-
3 
GS-Kmet  4.25 372.15 1.14 3.62 0.24 94-96  [41] Nd 
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Table 3. List of reference compounds for the development and evaluation of alternative methods to in vivo fish bioaccumulation 829 
studies (cont.) 830 
 831 
 832 
ID 
Cc 
(T1) 
Chemical name CAS RN 
Type 
(F1) 
Log 
Kow 
MW 
(g/mol) 
Dmax 
(nm) 
Log 
BCF 
 Kmet 
(1/d) 
MP and 
Ms (pp) 
Notes Ref 
Ref 
ed 
56 5 Tebuconazole 107534-96-
3 
GS-Kmet  3.89 307.82 1.31 3.32 0.55 97-98  [41] Nd 
57 5 Fipronil  120068-37-
3 
GS-Kmet  6.64 437.15 1.21 3.96 1.01 99-100 Highly volatile 
in solution 
[41] Nd 
58 5 1,6-Hexalactam  105-60-2 SP 0.66 113.16 0.51 0.50 11.38 101-102 HL=360 h [56] Nd 
59 5 Levamisole 14769-73-4 SP 2.87 204.29 1.06 2.43 1.10 103-104 HL=360 h [24] Nd 
60 5 Paramethadione 115-67-3 SP 1.08 157.17 0.74 0.86 2.92 105-106  [24] Nd 
61 5,9 4-Nitroquinoline oxide 56-57-5 SP 0.82 190.16 0.72 0.64 3.87 107 Highly volatile 
in solution 
[23] Nd 
62 5,9 Nitrofurantoin 67-20-9 SP -0.17 238.16 1.09 -0.23 37.60 108 Highly volatile 
in solution 
[23] Nd 
63 6 Triphenyl phosphite 101-02-0 GS-BCF  6.62 310.28 1.10 2.39 0.05 109 O2 [23] Nd 
64 6 Diazinon 333-41-5 SP 3.86 304.35 1.11 3.29 0.15 110-112  [23] [58] 
65 6 Chlorpyrifos 2921-88-2  SP 5.11 350.59 1.15 4.21 0.10 113-114  [23] [21] 
66 6 Cyanophos 2636-26-2  SP 2.76 243.22 1.08 2.34 0.15 115-116  [52] [52] 
67 6,7 Fenthion 55-38-9  SP 4.08 278.33 1.03 3.48 0.08 117-118  [52] [52] 
68 6,9 Methyl parathion 298-00-0 SP 2.75 263.21 1.06 2.33 0.22 119-120  [52] [52] 
69 6,9 Chlorothion 500-28-7 SP 3.39 297.65 0.93 2.89 0.14 121-122  [52] [52] 
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Table 3. List of reference compounds for the development and evaluation of alternative methods to in vivo fish bioaccumulation 833 
studies (cont.) 834 
ID 
Cc 
(T1) 
Chemical name CAS RN 
Type 
(F1) 
Log 
Kow 
MW 
(g/mol) 
Dmax 
(nm) 
Log 
BCF 
 Kmet 
(1/d) 
MP and 
Ms (pp) 
Notes Ref 
Ref 
ed 
70 6,9 Parathion 56-38-2  SP 3.73 291.26 1.16 3.18 0.12 123-124  [23] [58] 
71 7 Diphenyl disulfide 882-33-7  SP 4.31 218.34 0.92 3.67 0.29 125-126 HL=360 h [53] Nd 
72 7 Sulfanilamide 63-74-1  SP -0.55 172.20 0.76 -0.57 13.79 127  [54] Nd 
73 7 Dibenzothiophene 132-65-0  SP 4.17 184.26 0.85 3.55 0.23 128-129 HL=360 h [55] Nd 
74 7,10 Thiourea 62-56-6 SP -1.31 76.12 0.50 -1.23 37.60 130 HL=360 h [23] Nd 
75 7,10 Aldicarb 116-06-3  SP 1.36 190.26 0.88 1.11 3.21 131-132  [23] [58] 
76 7,12 Thiobencarb 28249-77-6 SP 3.90 257.78 1.36 3.33 1.07 133-134  [23] Nd 
77 7,5 Methimazole 60-56-0  SP -0.49 114.17 0.53 -0.51 25.46 135 HL=360 h [23] Nd 
78 8 Pimaric acid 127-27-5 GS-BCF  6.45 302.45 1.16 1.85 0.00 136-138 O2 1 Nd 
79 8 Isopimaric acid 5835-26-7 GS-BCF  6.45 302.45 1.15 1.54 0.00 139-141 O2 1 Nd 
80 8 Abietic acid 514-10-3 GS-BCF  6.46 302.45 1.16 1.84 0.00 142-144 O2 1 Nd 
81 8 Neoabietic acid 471-77-2 GS-BCF  6.59 302.45 1.16 2.10 0.00 145-147 O2 1 Nd 
82 8 Palustric acid 1945-53-5 GS-BCF  7.27 302.45 1.20 1.40 0.00 148-150 O2 1 Nd 
83 8 12,14-
Dichlorodehydroabietic acid 
57055-39-7 GS-BCF  7.81 369.33 1.20 1.97 0.00 151-152 O2 1 Nd 
84 8 Diclofenac 15307-86-5 GS-MP 4.02 296.15 0.96 3.43 0.03 153-155, 
T5 
Highly volatile 
in solution 
[49] Nd 
85 8 Naproxen 22204-53-1 GS-MP 3.10 230.26 1.21 2.64 0.12 156-
158,T5 
HL=360 h [49] Nd 
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Table 3. List of reference compounds for the development and evaluation of alternative methods to in vivo fish bioaccumulation 835 
studies (cont.) 836 
 837 
 838 
ID 
Cc 
(T1) 
Chemical name CAS RN 
Type 
(F1) 
Log 
Kow 
MW 
(g/mol) 
Dmax 
(nm) 
Log 
BCF 
 Kmet 
(1/d) 
MP and 
Ms (pp) 
Notes Ref 
Ref 
ed 
86 8 Ibuprofen  15687-27-1 GS-MP 3.79 206.28 1.03 3.23 0.11 159-
160,T5 
HL=360 h [49-
50] 
[70] 
87 9 1-Chloro-4-nitrobenzene 100-00-5 GS-BCF  2.46 157.55 0.66 2.00 0.34 161-162 W 1 Nd 
88 9 1-Chloro-2-nitrobenzene 88-73-3 GS-BCF  2.46 157.55 0.60 2.09 0.38 163-164 W 2 Nd 
89 9 1-Chloro-3-nitrobenzene 121-73-3 GS-BCF  2.46 157.55 0.61 1.89 0.32 165-166 W 2 Nd 
90 9 1,2-Dichloro-4-nitrobenzene 99-54-7 GS-BCF  3.10 192.00 0.71 2.07 0.19 167-168 O1 1 Nd 
91 9 1,4-Dichloro-2-nitrobenzene 89-61-2 GS-BCF  3.10 192.00 0.62 2.05 0.20 169-171 O1 2 Nd 
92 9 2,4-Dichloro-1-nitrobenzene 611-06-3 GS-BCF  3.10 192.00 0.62 2.07 0.20 172 O1 2 Nd 
93 9 1,3-Dichloro-5-nitrobenzene 618-62-2 GS-BCF  3.10 192.00 0.62 2.23 0.20 173 W 2 Nd 
94 9 1,2-Dichloro-3-nitrobenzene 3209-22-1 GS-BCF  3.10 192.00 0.62 2.16 0.20 174-175 W 2 Nd 
95 9 1,2,4,-Trichloro-5-
nitrobenzene 
89-69-0 GS-BCF  3.74 226.44 0.67 1.80 0.14 176-177 O2 2 Nd 
96 9 1,2,3-Trichloro-4-
nitrobenzene 
17700-09-3 GS-BCF  3.74 226.44 0.60 2.19 0.13 178-179 O2 2 Nd 
97 9 1,2,4,5-Tetrachloro-3-
nitrobenzene 
117-18-0 GS-BCF  4.39 260.89 0.62 3.20 0.07 180-181 O1 2 Nd 
98 9 1,2,3,4-Tetrachloro-5-
nitrobenzene 
879-39-0 GS-BCF  4.39 260.89 0.67 1.85 0.10 182-183 O2 2 Nd 
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Table 3. List of reference compounds for the development and evaluation of alternative methods to in vivo fish bioaccumulation 840 
studies (cont.) 841 
ID 
Cc 
(T1) 
Chemical name CAS RN 
Type 
 (F1) 
Log 
Kow 
MW 
(g/mol) 
Dmax 
(nm) 
Log 
BCF 
 Kmet 
(1/d) 
MP and 
Ms (pp) 
Notes Ref 
Ref 
ed 
99 10 Ethylamine 75-04-7 SP -0.15 45.08 0.44 -0.22 2.17 184-185 HL=360 h [55] Nd 
100 10 Butylamine 109-73-9 SP 0.83 73.14 0.70 0.64 0.97 186-188 HL=208 h [55] Nd 
101 10 Hexylamine 111-26-2 SP 1.82 101.19 0.95 1.51 0.47 189-191 HL=208 h [55] Nd 
102 10 2-Amino-2-propanol 78-96-6 SP -1.19 75.11 0.54 -1.13 8.33 192-193 HL=360 h [55] Nd 
103 10 Trimethylamine 75-50-3  SP 0.04 59.11 0.62 -0.05 10.14 194 HL=360 h [23] Nd 
104 11 N,N-Dimethylaniline 121-69-7 SP 2.17 121.18 0.94 1.82 2.81 195-196  [23] [58] 
105 11 2-Aminofluorene 153-78-6 SP 3.10 181.23 1.02 2.64 1.24 197-199  [23] Nd 
106 11 Kynurenine 343-65-7 SP -2.25 208.21 0.97 -2.06 19.68 200-201 HL=360 h. 
Highly volatile 
in solution 
[56] Nd 
107 11 Tryptamine 61-54-1  SP 1.27 160.22 0.93 1.03 0.58 202-204 HL=360 h [56] Nd 
108 11 Benzenamine 62-53-3  SP 1.08 93.13 0.61 0.86 6.40 205-206 HL=360 h [23] Nd 
109 12 Butyramide 541-35-5 SP -0.18 87.12 0.60 -0.24 27.92 207 HL=360 h [55] Nd 
110 12 E,E-N-Isobutyl-2,4-
decadienamide 
18836-52-7 SP 4.20 223.35 1.85 3.58 0.43 208-210 HL=360 h [55] Nd 
111 12 Acetyl-1-pyrroline 99583-29-6 SP 1.66 111.14 0.64 1.37 1.89 211-212 HL=360 h [55] Nd 
112 12 2-Isopropyl-N,2,3-
trimethylbutyramide 
51115-67-4 SP 2.48 171.28 0.78 2.09 2.18 213-214  [55] Nd 
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 842 
Table 3. List of reference compounds for the development and evaluation of alternative methods to in vivo fish bioaccumulation 843 
studies (cont.) 844 
50 
 
 845 
ID 
Cc 
(T1) 
Chemical name CAS RN 
Type 
(F1) 
Log 
Kow 
MW 
(g/mol) 
Dmax 
(nm) 
Log 
BCF 
 Kmet 
(1/d) 
MP and 
Ms (pp) 
Notes Ref 
Ref 
ed 
113 12 N-Ethyl(E)-2,(Z)-6-
nonadienamide 
608514-56-
3 
SP 2.80 181.27 1.39 2.37 1.09 215-216 HL=360 h [55] Nd 
114 12 Piperine 94-62-2 SP 3.69 285.34 1.53 3.15 0.22 217-219 Highly volatile 
in solution 
[55] Nd 
115 13 Acetaldehyde 75-07-0  SP -0.17 44.05 0.31 -0.23 3.82 220-221 HL=360 h [57] Nd 
116 13 Acrolein 107-02-8  SP 0.19 56.06 0.40 0.08 2.88 222-224 HL=360 h [58] Nd 
117 13 Endrin aldehyde 7421-93-4 SP 4.80 380.91 0.72 4.03 0.01 225-227  [58] Nd 
118 13 Formaldehyde 50-00-0 SP 0.35 30.03 0.18 0.22 3.79 228 HL=360 h [58] Nd 
119 14 Ethanol 64-17-5 SP -0.14 46.07 0.31 -0.21 7.28 229 HL=208 h [23] Nd 
120 14 Allyl alcohol 107-18-6 SP 0.21 58.08 0.43 0.10 4.94 230-231 HL=360 h [23] Nd 
121 14 1-Propanol 71-23-8 SP 0.35 60.10 0.43 0.22 5.03 232-233 HL=360 h [59] Nd 
122 14 Cyclohexanol 108-93-0 SP 1.64 100.16 0.50 1.36 2.01 234-235 HL=360 h [60] Nd 
123 15 Pentachlorophenol 87-86-5 GS-BCF  4.74 266.34 0.62 2.65 0.09 236 O2 1 [71] 
124 15 4,5-Dichloro-2-
methoxyphenol 
2460-49-3 GS-BCF  2.63 193.03 0.77 2.03 0.61 237-238 W 1 Nd 
125 15 2-Methoxytetrachlorophenol 2539-17-5 GS-BCF  3.92 261.92 0.81 2.26 0.04 239 O2 1 Nd 
126 15 Phenol 108-95-2 SP 1.51 94.11 0.50 1.24 6.61 240-241 HL=360 h [57] [58] 
127 16 Phenanthrenequinone 84-11-7 SP 3.56 208.21 0.93 3.04 0.44 242-243  [23] Nd 
51 
 
Table 3. List of reference compounds for the development and evaluation of alternative methods to in vivo fish bioaccumulation 846 
studies (cont.) 847 
 848 
 849 
 850 
ID 
Cc 
(T1) 
Chemical name CAS RN 
Type 
(F1) 
Log 
Kow 
MW 
(g/mol) 
Dmax 
(nm) 
Log 
BCF 
 Kmet 
(1/d) 
MP and 
Ms (pp) 
Notes Ref 
Ref 
ed 
128 16 9,10-Anthraquinone 84-65-1 SP 3.34 208.21 0.96 2.84 0.54 244  [61] Nd 
129 16 1,4-Benzoquinone 106-51-4  SP 0.25 108.09 0.49 0.14 10.88 245 HL=360 h [62] Nd 
130 16 1,4-Naphthoquinone 130-15-4 SP 1.66 158.15 0.72 1.37 0.58 246-247 HL=360 h [63] Nd 
131 16 2-Hydroxy-1,4-
naphthoquinone 
83-72-7  SP 0.78 174.15 0.81 0.60 1.16 248-249 HL=360 h [64] Nd 
132 17 2-Ethenyloxirane 930-22-3 SP 0.73 70.09 0.56 0.56 2.69 250-251 HL=360 h [65] Nd 
133 17 1,2-Epoxyoctane 2984-50-1 SP 2.83 128.21 1.05 2.40 0.68 252-253 HL=360 h [65] Nd 
134 17 9,10-Phenanthrene oxide 585-08-0 SP 3.22 194.23 0.85 2.74 1.59 254-255 HL=360 h [65] Nd 
135 17 1-Phenyloxirane 96-09-3 SP 1.59 120.15 0.73 1.31 5.73 256-257 HL=360 h [65] Nd 
136 17 (2R,3S)-2,3-diphenyloxirane 1439-07-2 SP 3.22 196.24 1.16 2.74 5.20 258-259 HL=360 h [65] Nd 
137 18 Arachidonic acid 506-32-1  SP 8.07 304.47 2.65 2.81 0.01 260-262 HL=360 h. 
Highly 
lipophilic 
[23] Nd 
138 18 Eicosapentaenoic acid 25378-27-2 SP 7.85 302.45 2.52 3.00 0.00 263-266 HL=360 h [23] Nd 
139 18 Docosahexaenoic acid 6217-54-5  SP 8.62 328.49 1.23 2.34 0.00 267-270 HL=360 h. 
Highly 
lipophilic 
[23] Nd 
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CAS RN: Chemical Abstracts Service Registry Number, Cc: Chemical class according to Table 1, Dmax: Maximum inter-atomic distance 851 
between two atoms in the chemical structure (nm) calculated using MOPAC v.2012, ID: Identification number, Kmet: Whole body 852 
biotransformation rate (1/day (d)). In vivo values for GS-Kmet compounds and in silico values for GS-BCF, GS-MP and SP obtained from 853 
BCFBAF v.3.01 for one Kg fish, Log BCF: Logarithm of the average of bioconcentration factor (BCF) values (L/Kg ww (wet weight)). In vivo 854 
values for GS-BCF compounds and in silico values for GS-Kmet, GS-MP and SP compounds obtained from Equation 2, Log Kow: Logarithm of 855 
octanol-water partition coefficient calculated from KOWWIN v.1.68, MP: Metabolic pathway. In vivo biotransformation routes for GS-MP 856 
compounds are showed in Table 5 (T5). Predicted metabolic pathways for all reference compounds were calculated using Meteor software and 857 
are provided in Supplementary Information (pages (pp), Ms: Resulting metabolites from the parent compound. Metabolites analysed in a in vivo 858 
systems for GS-MP compounds are showed in Table 5 (T5). Structures of potential metabolites were calculated using Meteor software and are 859 
provided in Supplementary Information (pages (pp), Notes: HL: Half-Life (h: hours) calculated from Fugacity model from the EpiSuite v.4.1, W: 860 
well-predicted compounds (residuals < 0.5 log units), O1: marginally over-predicted compounds (residuals > 0.5 log units), O2: highly over-861 
predicted compounds (residuals > 1 log units) and U: under-predicted compounds according to Equation 2, Ref: Reference (1: DSL 862 
Environment Canada BCF database, 2: non-DSL Environment Canada BCF database, 3: Common between EURAS-CEFIC database and 863 
DSL/non-DSL Environment Canada BCF database), Ref ed:  Reference of exiting in vitro data in rainbow trout, Type: Type of compound 864 
according to Figure 1. GS-BCF: Gold-Standard BCF compounds, GS-Kmet: Gold-Standard- Kmet compounds, GS-MP: Gold-Standard metabolic 865 
pathway compounds, SP: Supplementary compounds.  866 
 867 
  868 
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Table 4. Experimental details of Gold-Standard BCF compounds 869 
Table 4. Experimental details of Gold-Standard BCF compounds (cont.) 870 
ID CAS RN Chemical name n 
BCF 
Log 
BCF 
CV Test 
concentration 
(µg/L) 
Uptake 
phase 
(days) 
T (°C) Rng  
Wwf (g) 
Rng lipid 
content 
(%) 
DB 
1 (48) 520-45-6 Dehydroacetic acid 4 2.12 0.36 3.6 5 to 20 15 140 Nd 1 
2 (87) 100-00-5 1-Chloro-4-nitrobenzene 5 2 0.11 0.78 5 to 36 15 165 8.40 1 
3 (88) 88-73-3 1-Chloro-2-nitrobenzene 5 2.09 0.26 0.72 5 to 36 15 165 8.40 2 
4 (89) 121-73-3 1-Chloro-3-nitrobenzene 5 1.89 0.15 0.8 5 to 36 15 165 8.40 2 
5 (124) 2460-49-3 4,5-Dichloro-2-methoxyphenol 1 2.03 0 7 20 15 140 8.00 1 
6 (90) 99-54-7 1,2-Dichloro-4-nitrobenzene 5 2.07 0.1 0.73 5 to 36 15 165 8.40 1 
7 (91) 89-61-2 1,4-Dichloro-2-nitrobenzene 5 2.05 0.06 0.77 5 to 36 15 165 8.40 2 
8 (92) 611-06-3 2,4-Dichloro-1-nitrobenzene 5 2.07 0.04 0.75 5 to 36 15 165 8.40 2 
9 (93) 618-62-2 1,3-Dichloro-5-nitrobenzene 5 2.23 0.05 0.76 5 to 36 15 165 8.40 2 
10 (94) 3209-22-1 1,2-Dichloro-3-nitrobenzene 5 2.16 0.07 0.77 5 to 36 15 165 8.40 2 
11 (10) 95-50-1 1,2-Dichlorobenzene 10 2.58 0.43 0.05,0.94 7 to 119 15 242-400 7.2-10.7 1 
12  106-46-7 1,4-Dichlorobenzene 21 2.76 0.47 0.03,0.07,0.08,0.67 7 to 119 15 175-400 5.0-10.7 1 
13 (11) 541-73-1 1,3-Dichlorobenzene 10 2.74 0.36 0.03,0.69 7 to 119 15 242-400 7.2-10.7 1 
14 (95) 89-69-0 1,2,4-Trichloro-5-nitrobenzene 5 1.8 0.18 0.68 5 to 36 15 165 8.40 2 
15 (96) 17700-09-3 1,2,3-Trichloro-4-nitrobenzene 5 2.19 0.23 0.66 5 to 36 15 165 8.40 2 
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 871 
  872 
ID CAS RN Chemical name 
n 
BCF 
Log 
BCF 
CV 
Test 
concentration 
(µg/L) 
Uptake 
phase 
(days) 
T (°C) 
Rng  
Wwf  (g) 
Rng lipid 
content 
(%) 
DB 
16 18708-70-8 1,3,5-Trichloro-2-nitrobenzene 5 2.92 0.24 0.54 5 to 36 15 165 8.40 2 
17 (15) 108-36-1 1,3-Dibromobenzene 1 2.82 0 <0.01 90 15 280 Nd 3 
18 (125) 2539-17-5 2-Methoxytetrachlorophenol 1 2.26 0 1 20 15 140 8 1 
19 (12) 87-61-6 1,2,3-Trichlorobenzene 8 3.26 0.43 <0.01,0.07 22 to 119 15 277-400 8-10.7 1 
20  108-70-3 1,3,5-Trichlorobenzene 8 3.49 0.64 <0.01,0.04 22 to 119 15 277-400 8-10.7 1 
21  120-82-1 1,2,4-Trichlorobenzene 20 3.38 0.51 <0.01,0.05 7 to 119 15 183-400 6.3-10.7 1 
22 (27) 54135-80-7 
1,2,3-Trichloro-4-
methoxybenzene 
13 3.25 0.32 <0.01*,0.01,0.07 7 to 96 15 183-400 6.3-10.7 3 
23 67-72-1 Hexachloroethane 10 2.84 0.57 <0.01,<0.01 7 to 119 15 242-400 7.2-10.7 1 
24 (25) 320-60-5 
2,4-Dichloro-1-
(trifluoromethyl)benzene 
10 3.52 0.34 0.03,0.21 21 to 96 15 183-312 5.0-8.0 2 
25 (26) 328-84-7 
1,2-Dichloro-4-
(trifluoromethyl)benzene 
1 3.18 0 <0.01 90 15 280 Nd 3 
26 (1) 58-89-9 γ-Lindane 12 3.13 0.45 <0.01,0.03,2.01* 5 to 96 15 175-312 5.3-8.0 1 
27 (97) 117-18-0 
1,2,4,5-Tetrachloro-3-
nitrobenzene 
12 3.2 0.36 <0.01,0.01,0.64 20 to 96 15 165-312 6.9-8.0 2 
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Table 4. Experimental details of Gold-Standard BCF compounds (cont.) 873 
 874 
 875 
 876 
  877 
ID CAS RN Chemical name 
n 
BCF 
Log 
BCF 
CV 
Test 
concentration 
(µg/L) 
Uptake 
phase 
(days) 
T (°C) 
Rng  
Wwf  (g) 
Rng lipid 
content 
(%) 
DB 
28 (98) 879-39-0 
1,2,3,4-Tetrachloro-5-
nitrobenzene 
8 1.85 0.47 <0.01,0.61 12 to 96 15 165-288 6.7-8.4 2 
29 (40) 1825-31-6 1,4-Dichloronaphthalene 1 3.75 0 <0.01 90 15 280 Nd 3 
30 (19) 6639-30-1 
1,2,4-Trichloro-5-
methylbenzene 
10 3.88 0.24 <0.01,<0.01,0.05 21 to 96 15 202-312 5.0-8.0 3 
31 95-94-3 1,2,4,5-Tetrachlorobenzene 7 3.9 0.53 <0.01,0.02 39 to 119 15 202-312 5.0-8.0 1 
32 (13) 634-66-2 1,2,3,4-Tetrachlorobenzene 17 3.85 0.38 <0.01,<0.01,0.03 39 to 119 15 258-312 7.0-10.70 1 
33 (16) 626-39-1 1,3,5-Tribromobenzene 11 4.02 0.33 <0.01,<0.01*,0.02 4 to 96 15 183-312 6.90-8.0 3 
34 (17) 615-54-3 1,2,4-Tribromobenzene 1 3.63 0 <0.01 90 15 280 Nd 3 
35  87-68-3 Hexachlorobutadiene 10 3.94 0.62 <0.01,<0.01 7 to 119 15 242-400 7.20-10.70 1 
36 (123) 87-86-5 Pentachlorophenol 2 2.65 0.11 91.2 6 12.5 19- 39 6.30-8.95 1 
37  82-68-8 Pentachloronitrobenzene 14 2.41 0.74 <0.01,0.01,0.69 5 to 96 15 165-312 6.30-8.45 2 
38 (30) 16605-91-7 2,3-Dichloro-1,1'-biphenyl 3 4.08 0.08 <0.01 75 to 96 15 223-278 6.60-8.20 2 
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Table 4. Experimental details of Gold-Standard BCF compounds (cont.) 878 
 879 
 880 
  881 
ID CAS RN Chemical name 
n 
BCF 
Log 
BCF 
CV 
Test 
concentration 
(µg/L) 
Uptake 
phase 
(days) 
T (°C) 
Rng  
Wwf  (g) 
Rng lipid 
content 
(%) 
DB 
39 (31) 34883-39-1 2,5-Dichloro-1,1'-biphenyl 4 3.98 0.24 0.01 35 to 96 15 191-341 6.60-8.20 2 
40 (32) 34883-41-5 3,5-Dichloro-1,1'-biphenyl 4 3.77 0.1 0.02 35 to 96 15 191-341 6.60-8.20 2 
41 (14) 608-93-5 Pentachlorobenzene 6 4.19 0.29 <0.01,<0.01 43 to 119 15 277-400 8.20-10.70 1 
42 (28) 1825-21-4 Pentachloroanisole 8 4.19 0.26 <0.01,0.01 35 to 96 15 202-312 6.70-8.0 2 
43 (18) 636-28-2 1,2,4,5-Tetrabromobenzene 8 3.67 0.35 <0.01,0.02 35 to 96 15 202-312 6.70-8.0 3 
44 (21) 877-10-1 
1,2,4,5-Tetrachloro-3,6-
dimethylbenzene 
3 3.55 0.41 0.01 50 to 96 15 262-288 6.70-8.0 2 
45 (33) 37680-65-2 2,2',5-Trichloro-1,1'-biphenyl 2 4.23 0 0.02 75 to 96 15 278-341 6.60-8.20 2 
46 (34) 20020-02-4 
1,2,3,4-
Tetrachloronaphthalene 
4 3.7 0.07 <0.01 35 to 96 15 191-341 6.60-8.20 2 
47 (22) 877-11-2 Pentachloromethyl benzene 4 3.83 0.07 <0.01 35 to 96 15 191-341 6.60-8.20 2 
48 (35) 38444-93-8 
2,2',3,3'-Tetrachloro-1,1'-
biphenyl 
2 4.23 0.03 2.8 14 to 20 15 140 Nd 2 
49 (78) 127-27-5 Pimaric acid 2 1.85 0.02 2.7 14 to 20 15 140 Nd 1 
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Table 4. Experimental details of Gold-Standard BCF compounds (cont.) 882 
 883 
CAS RN: Chemical Abstracts Service Registry Number, CV: Coefficient of variance, DB: Database reference (1: DSL Environment Canada BCF 884 
database, 2: non-DSL Environment Canada BCF database, 3: Common between EURAS-CEFIC database and DSL/non-DSL Environment 885 
Canada BCF database), ID: Identification number (identification number in Table 3), Log BCF: Logarithm of the average of bioconcentration 886 
factor (BCF) values (L/Kg ww (wet weight)), Nd: No data reported, T: Temperature (°C), Rng ww: Range of final wet weight (mg) of test species, 887 
Rng lipid content: range of final lipid content (%) of test species. 888 
  889 
ID CAS RN Chemical name 
n 
BCF 
Log 
BCF 
CV 
Test 
concentration 
(µg/L) 
Uptake 
phase 
(days) 
T (°C) 
Rng  
Wwf (g) 
Rng lipid 
content 
(%) 
DB 
50 (79) 5835-26-7 Isopimaric acid 2 1.54 0.02 2.7 14 to 20 15 140 Nd 1 
51 (80) 514-10-3 Abietic acid 2 1.84 0.01 2.1 14 to 20 15 140 Nd 1 
52 (81) 471-77-2 Neoabietic acid 2 2.1 0.05 0.7 14 to 20 15 140 Nd 1 
53 (63) 101-02-0 Triphenyl phosphite 1 2.39 0 0.81 96 12 Nd Nd 1 
54 (23) 87-83-2 Pentabromomethylbenzene 4 2.43 0.15 <0.01 35 to 96 15 191-341 6.60-8.20 2 
55 (82) 1945-53-5 Palustric acid 2 1.4 0 1.1 14 to 20 15 140 Nd 1 
56 (18) 87-82-1 Hexabromobenzene 5 3.02 0.22 <0.01 21 to 96 15 191-341 6.60-8.20 2 
57 (24) 85-22-3 Pentabromoethylbenzene 4 2.52 0.13 <0.01 35 to 96 15 191-341 6.60-8.20 2 
58 (83) 57055-39-7 
12,14-Dichlorodehydroabietic 
acid 
2 1.97 0.02 3.2 14 to 20 15 140 Nd 1 
59 (41) 2234-13-1 Octachloronaphthalene 2 2.58 0.2 0.01 75-96 15 278-341 6.60-8.20 2 
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Table 5. Experimental details of Gold-Standard metabolic compounds 890 
ID CAS NR Chemical name 
Kmet 
(1/d) 
Metabolites 
analysed 
Metabolic 
pathway 
proposed 
TE FTA 
   E  
(days) 
  TC 
(g/g 
ww or 
g/L) 
  T 
(°C) 
Wwi 
(g) 
Ref 
1 (50) 88671-89-0 Myclobutanil 0.200 Nd Nd DM C 8 30.15 12 18 [41] 
2 (51) 60207-90-1 Propiconazole 0.572 Nd Nd DM C 8 24.96 12 18 [41] 
3 (52) 94361-06-5 Cyproconazole 0.369 Nd Nd DM C 8 23.83 12 18 [41] 
4 (53) 66246-88-6 Penconazole 0.211 Nd Nd DM C 8 31.46 12 18 [41] 
5 (54) 125116-23-6 Metconazole 0.580 Nd Nd DM C 8 28.14 12 18 [41] 
6 (55) 43121-43-3 Triadimefon 0.541 Nd Nd DM C 8 29.02 12 18 [41] 
7 (56) 112281-77-3 Tetraconazole 0.237 Nd Nd DM C 8 30.95 12 18 [41] 
8 (57) 107534-96-3 Tebuconazole 0.552 Nd Nd DM C 8 26.43 12 18 [41] 
9 (58) 120068-37-3 Fipronil 1.006 Nd Nd DM C 32 7.68 12 10 [42] 
10 (36) 50-29-3 p,p'-Dichlorodiphenyltrichloroethane 0.011 Nd Nd DM C 32 0.42 12 10 [42] 
11 (35) 38444-93-8 2,2',3,3'-Tetrachlorobiphenyl 0.001  OH-PCBs Hydroxylation DM C 30 <0.01 12 80 [43] 
12 (37) 38380-05-1 2,2',3,3',4,6'-Hexachlorobiphenyl 0.004 OH-PCBs Hydroxylation DM C 30 0.04 12 80 [43] 
13 (38) 52744-13-5 2,2',3,3',5,6'-Hexachlorobiphenyl <0.001  OH-PCBs Hydroxylation DM C 30 0.03 12 80 [43] 
14 (39) 38411-22-2 2,2',3,3',6,6'-Hexachlorobiphenyl 0.002 OH-PCBs Hydroxylation DM C 30 0.02 12 80 [43] 
15 (2) 754-91-6 Perfluorooctanesulfonamide Nd PFOS Nd DM M 30 10.9 12 Nd [45] 
 891 
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Table 5. Experimental details of Gold-Standard metabolic compounds (cont.) 892 
Table 5. In vivo experimental data for Gold-Standard metabolic compounds (cont.) 893 
ID CAS NR Chemical name 
Kmet 
(1/d) 
Metabolites 
analysed 
Metabolic 
pathway 
proposed 
TE FTA 
  E  
(days) 
  TC 
(g/g 
ww, 
g/L) 
  T 
(°C) 
Wwi 
(g) 
Ref 
16 (3) 865-86-1 10:2 Fluorotelomer alcohol Nd 10:2 FTCA 
10:2 FTUCA 
Nd DM M 30 5.00 12 Nd [45] 
17 (4) 678-39-7 8:2 Fluorotelomer alcohol Nd 8:2 FTCA 
8:2 FTUCA 
Nd DM M 30 6.70 12 Nd [46] 
18 (5) 27905-45-9 8:2 Fluorotelomer acrylate Nd 
8:2 FTOH 
8:2 FTUCA 
7:3 FTCA 
8:2 FTCA 
PFOA 
8:2FTOH-Glu 
-like oxidation 
mechanism: 
8:2FTUCA>7:3 
-keto acid>7:2 
ketone>PFOA 
DM 
L,Bl,
k,Bi 
5 93.00 18 45 [47] 
19 (29) 1163-19-5 Decabromodiphenyl ether Nd 
De-BDEs 
MeO-BDEs 
Nd II 
M,L,
Bl 
28 0.1;0.5 15 100 [47] 
20 (84) 15307-86-5 Diclofenac Nd 
4'-OH-DCF 
5-OH-DCF 
DCF- A.Glu  
4'-OH-DCF-Sul 
5-OH-DCF-Sul 
4'-OH-DCF-A.Glu   
5-OH-DCF- A.Glu 
3'-OH-DCF-A.Glu 
4'-OH-DCF-E.Glu 
Hydroxylation> 
Glucuronidation 
Sulfatation 
 
WM Bi 10 1.8;43 14 33 [48] 
21 (85) 22204-53-1 Naproxen  Nd 
DNPX 
NPX-A.Glu 
DNPX-A.Glu 
Demethylation> 
Glucuronidation 
WM Bi 10 1.6;40 14 33 [48] 
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ID CAS NR Chemical name 
Kmet 
(1/d) 
Metabolites 
analysed 
Metabolic 
pathway 
proposed 
TE FTA 
   E  
(days) 
  TC 
(g/g 
ww, 
g/L) 
  T 
(°C) 
Wwi 
(g) 
Ref 
22 (86) 15687-27-1 Ibuprofen  
Nd 
Carboxyl-IBF 
2-OH-IBF 
IBF-A.Glu 
OH-IBFs--A.Glu 
Hydroxylation> 
Glucuronidation 
Sulfatation 
WM Bi 10 1;25 14 33 [48] 
Nd 
2-OH-IBF 
3-OH-IBF 
IBF-A.Glu 
OH-IBFs-A.Glu 
IBF-Tau 
Nd WS Bi 4 
0.17;1.
9;13;1
45 
14 58 [49] 
CAS RN: Chemical Abstracts Service Registry Number, DNPX: 6-O-desmethylnaproxen, E: Exposure duration (days) (Including 894 
uptake phase and intraperitoneal injection),FTA: Fish target analysed (Bi: Bile, Bl: Blood, C: Carcas, L: Liver, K: Kidney, M: Muscle), 895 
IBF: Ibuprofen, ID: Identification number (identification number in Table 3), Kmet: Whole body biotransformation rate (1/days), Nd: No 896 
data reported, NPX: Naproxen, Ref: Reference, T: Temperature (°C), TC: Test concentration (Dietary and Intraperitoneal injection 897 
exposure: g/g ww, waterborne exposure: g/L), TE: Type of exposure (D: Dietary, W: Waterborne, S: Single, M: Mixture of 898 
chemicals, II: Intraperitoneal injection), Wwi: Initial wet weight of fish (mg),Metabolites (PFOS: Perfluorooctanesulfonate, FTCA: 899 
Fluorotelomer saturated acid, FTUCA: Fluorotelomer unsaturated acid, FTOH: Fluorotelomer alcohol, FTOH-Glu: Fluorotelomer 900 
glucuronide conjugate, PFOA: perfluorooctanoate, De-BDEs: Debrominated diphenyl ethers,MeO-BDEs: Methoxylated brominates 901 
diphenyl ethers, OH-DCF: Hydroxylated diclofenac, DCF-A.Glu: Acyl glucuronide of E.Glu: Ether glucuronide of hydroxylated 902 
diclofenac,NPX-A.Glu: Acyl glucuronide of naproxen,DNPX-A.Glu: Acyl glucuronide of 6-O-desmethylnaproxen, Carboxyl-903 
IBF:Carboxyl ibuprofen,OH-IBF: Hydroxylated ibuprofen,IBF-A.Glu: Acyl glucuronide of ibuprofen,OH-IBF-A.Glu: Acyl glucuronide 904 
of hydroxylated ibuprofen, IBF-Tau: Taurine conjugate of ibuprofen). 905 
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 906 
 907 
